Table 2.

Factors used for qualification to CLKT/SLKT

Indication	Factors	Citation
Hyperoxaluria type I (PH1)	High oxalate burden, not responding to pharmacological treatment CKD stage 4: eGFR < 29 ml/min/1.73 m2 (optional; SLKT) CKD stage 5: eGFR < 15 ml/min/1.73 m2 (direct; CLKT)	[23–25]
Autosomal recessive polycystic kidney disease (ARPKD)	PELD score > 10 (age, albumin, bilirubin, INR, growth failure) and therapy-resistant portal hypertension/ascending cholangitis/pruritus Complications of portal hypertension Complications of biliary tract (cholangitis) Severe cirrhosis in liver biopsy CKD stage 5: eGFR < 15 ml/min/1.73 m2/dialysis (CLKT) Availability of size-matched deceased donor of liver and kidney	[31–37]
CKD after liver transplantation	Hepatorenal syndrome (optional for SLKT), if dialysis after liver transplantation needed for > 6 weeks (renal biopsy needed for final decision) CKD stage 4: eGFR < 30 ml/min/1.73 m2 or CKD stage 5: eGFR < 15 ml/min/1.73 m2 Severe chronic damage in renal biopsy (tubulointerstitial fibrosis > 35%; glomerulosclerosis > 35%) (SLKT) * *data from adult setting	[58, 60–63]

ARPKD autosomal recessive polycystic kidney disease, PELD pediatric end-stage liver disease (score), INR international normalized ratio, CKD chronic kidney disease, CLKT combined liver–kidney transplantation, SLKT sequential liver–kidney transplantation; eGFR estimated glomerular filtration rate, PH1 primary hyperoxaluria type I